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Summary 
Abnormal humoral responses toward motor end plate constituents in muscle induce myasthenia 
gravis (MG). To study the etiology of this disease, and whether it could be induced by host 
defense molecules, we examined the consequences of interferon (IFN) "y production within the 
neuromuscular junction of transgenic mice. The transgenic mice exhibited gradually increasing 
muscular weakness, flaccid paralysis, and functional disruption of the neuromuscular junction 
that was reversed after administration of an inhibitor of acetylcholinesterase, features which are 
strikingly similar to human MG. Furthermore, histological examination revealed infiltration of 
mononuclear cells and autoantibody eposition at motor end plates. Immunoprecipitation analysis 
indicated that a previously unidentified 87-kD target antigen was recognized by sera from transgenic 
mice and also by sera from the majority of human MG patients tudied. These results suggest 
that expression of IFN-'y at motor end plates provokes an autoimmune humoral response, similar 
to human MG, thus linking the expression of this factor with development of this disease. 
utoimmune responses to neuromuscular junction com- 
ponents in myasthenia gravis (MG), 1 such as the nico- 
tinic acetylcholine r ceptor (nAChR), are largely pathogenic 
humoral responses. Patients uffer from progressive weakness 
of the voluntary muscles and many have autoantibodies against 
the nAChR, and a similar experimental condition, ex- 
perimental autoimmune MG (EAMG), can be induced by 
the introduction of antibodies to the nAChR (1-3). Addi- 
tionaUy, autoantibodies that impair neuromuscular transmis- 
sion have been found in some MG patients who lack autoan- 
tibodies to nAChR (4-7). 
Despite suggestions that viral or bacterial infections may 
trigger human MG, the molecular events leading to the de- 
velopment of the autoimmune r sponse against he neuromus- 
cular junction components remain unknown (8-10). The em- 
phasis on primary pathogenic effects of autoantibodies is 
relatively uncommon among autoimmune phenomenon with 
the exception of an another neuronal disorder, stiff-man syn- 
drome (11). 
We sought to address the mechanism by which cells of 
the immune system become sensitized to components in the 
neuromuscular junction. Our previous tudies have focused 
on the effects of cytokines elicited after infection or insult 
and that are capable of stimulating an immune response. While 
the autoimmune r sponse in the neuromuscular junction of 
MG patients is quite distinct from that observed in other 
autoimmune disorders, we performed studies to determine 
whether molecules produced uring the host response to in- 
fection could cause this type of disorder. We chose to study 
the effects of neuromuscular junction expression of the Thl 
lymphokine IFN-% which has a multitude of immunostimula- 
tory properties (12). 
1 Abbreviations u ed in this ~per: r c~-bungarotoxin; EAMG, 
experimental autoimmune myasthenia gravis; EM, electron microscopy; 
EMG, electromyogram; H & E, hematoxylin a d eosin; MG, myasthenia 
gravis; nAChR, nicotinic acetylcholine r ceptor; PSMP, postsynaptic 
membrane protein. 
Materials and Methods 
Production of6-IFN-7-tmnsgenic Mic~ The gene ncoding IFN-'y 
was inserted into the BamHI restriction site of the 3.5-kb e gene 
fragment containing the promoter region (13). An 8.8-kb XhoI/SpeI 
fragment containing the murine e promoter, the routine IFN-'y 
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gene, and a terminator sequence were excised and purified for oo- 
cyte injection as described previously (14). 
DNA Analysis. Southern blot analysis of genomic DNA was 
performed. 10 mg of genomic DNA, extracted from 2-cm-long 
tail segments, was digested with AccI enzyme overnight. The DNA 
was electrophoresed on0.8% agarose gels and transferred to nitrocel- 
lulose membranes (NitroPure; Micron Separations Inc., Westboro, 
MA). Hybridization was performed with radiolabeled restriction 
fragments of the IFN-~' cDNA clone (Prime-It TM random primer 
labeling kit; Stratagene Inc., La Jolla, CA). 
In Situ Hybridization. In situ hybridization confirmed that IFN-y 
was expressed in neuromuscular junctions of e-IFN-3~-transgenic 
mice. Skeletal muscles from 4-mo-old e-IFNq,-transgenic mice were 
placed in Bouin's fixative overnight. Deparaffinized sections were 
prehybridized for 2-3 h at 42~ in a buffer of 50% formamide, 
0.3 M NaC1, 20 mM Tris, pH 8.0, 5 mM EDTA, lx Denhardt's 
solution, 10% dextran sulfate, and 10 mM dithiothreitol. Hybrid- 
ization with 3sS-labeled sense and antisense RNA probes (750,000 
cpm/section) was done for 16 h at 42~ in a humidified chamber. 
This was followed by washing, dehydration, and drying. Sections 
were covered with nuclear track emulsion (NTB-2; Eastman Kodak 
Co., Rochester, NY), exposed for 1 wk, and developed. RNA probes 
were prepared by in vitro transcription of linearized plasmid con- 
taining IFN-y cDNA. No significant signals were seen with sense 
probes. 
Antibody Purification. The isolation and purification of e-trans- 
genic BALB/c mice and human IgG was performed by use of a 
protein A/G IgG purification kit (Pierce Chemical Co., Rock- 
ford, IL). 
Serum Collection. Sera from MG patients and patients with non- 
myasthenic disorders were supplied by the laboratories of Drs. H. 
Fox and J. Lindstrom with the help of Dr. Marjorie Seybold (The 
Scripps Research Institute). The sera were either stored at 4~ or 
- 70oC. 
Anti-nAChR Antibody Assay. nAChgs were isolated from the 
mouse cell line BC3H-1 (15). The assay for anti-nAChR antibody 
was performed as follows: 5-#1 aliquots of mouse sera were incubated 
overnight at 4~ with 10 -9 M nAChR labeled with 2 x 10 -9 M 
125I-oeBTX in 100 /zl of PBS (pH 7.5) containing 0.5% Triton 
X-100, and 10 mM NAN3.40/zl of 10% fixed Staphylococcus a reus 
A (Zysorbin; Zymed Labs, Inc., South San Francisco, CA) were 
then added and incubated for 75 rain. After dilution with 1 ml 
of the same buffer, the S. aureus-antibody-labeled nAChR precipi- 
tate was pelleted for 5 min in a microfuge. The pellet was washed 
twice, and then the tubes were counted for radioactivity. A blank 
value obtained by using 5 #1 of normal mouse serum in the assay 
was subtracted from all measurements. All assays were done in 
triplicate. 
Protein Analysis. Protein analyses were performed on muscle 
homogenates, crude cell extracts, and purified nAChR preparations 
by use of SDS-PAGE. The muscle homogenate was prepared by 
disrupting muscle tissue in PBS with a homogenizer (Tissumizer; 
Tekmar, Cincinnati, OH), and the crude and purified nAChRs were 
prepared as mentioned above. All samples received an equal volume 
of 2 x SDS-gel loading buffer (100 mM Tris-HC1, pH 6.8, 200 
mM dithiothreitol, 4% SDS, electrophoresis grade, 0.2% bromo- 
phenol blue; 20% glycerol) and were boiled for 10 min. For homo- 
genates, the samples were centrifuged at 14,000 rpm for 10 min, 
and the supernatants were transferred to fresh tubes. To perform 
gel electrophoresis, a 30-#g aliquot of protein muscle homogenates 
or an 8-/~1 aliquot of crude cell extracts (14 nM/#l) was loaded 
onto 1.5-mm-thick Tris-glycine 10% polyacrylamide slab gels (Tris- 
glycine electrophoresis buffer: 25 mM Tris base, 250 mM glycine, 
pH 8.3, 0.1% SDS). After SDS-PAGE (16), proteins were electro- 
transferred for 1.5-2 h to membranes (Immobilon; Millipore, Bed- 
ford, MA) (transfer buffer: 39 mM glycine, 48 mM "Iris base, 
0.037% SDS, 20% methanol). The membranes were subsequently 
probed with either purified IgG from the sera of e-transgenic mice 
(1:100), sera from patients with MG, sera from patients with non- 
myasthenic disorders, or the rabbit anti-87-kD postsynaptic mem- 
brane protein polypeptide antibodies of #625 and #638 (1:2,000; 
gifts from Dr. R. L. Huganir, Howard Hughes Medical Institute, 
The Johns Hopkins University School of Medicine, Baltimore, MD). 
After being probed with IgG or sera, the bound antibodies were 
detected with peroxidase-conjugated goat anti-mouse IgG (1:5,000; 
Boehringer Mannheim Corp., Indianapolis, IN), goat anti-human 
Igs (1:1,000; Sigma Chemical Co., St. Louis, MO), or goat anti- 
rabbit IgG (1:2,000; Tago, Inc., Burlingame, CA). Finally, peroxi- 
dases on the membranes were visualized with enhanced chemolumi- 
nescence (Amersham Life Science, Amersham, UK). 
Immunoprecipitations. To reveal the antigenic omponents reac- 
tive to transgenic mouse IgG, we performed immunoprecipitation 
using IgG from BALB/c transgenic mice, MG patients, and anti- 
87-kD-postsynaptic membrane protein polypeptide antibodies #625 
and #638. The crude cell extracts were isolated from both mouse 
BC3H-1 and human TE671 muscle cell lines (17) that were 
precleared with protein A-Sepharose and protein G-Sepharose 4B 
Fast Flow beads (Sigma Chemical Co.). To form immunocomplex, 
the IgG preparations (100 #g for mouse IgG, 150 #g for MG pa- 
tients, and 1 #g of anti-87-kD-postsynaptic membrane protein poly- 
peptide antibodies #625 and #638) were added separately to25/xl 
each ofprecleared nAChRs. After 1-h incubation at 4~ the mix- 
tures were reacted with excessive protein A and protein G-Sepharose 
beads. The antigen-antibody complexes bound to the beads were 
recovered by sedimentation by microfuge and washed with Tris 
buffer (0.1 M Tris-HC1, pH 7.4, 0.15 M NaC1, 0.01 M EDTA, 
2% Triton X-100), repelleted, resuspended in 30 #1 of I x SDS 
loading buffer, heated in boiling water for 5 min, and pelleted in 
a microfuge. The proteins in both Sepharose bead-bound pellets 
and supernatants were analyzed by SDS-PAGE. 
Histological nd Immunocytochemical An ysis. Tissues were fixed 
in Bouin's fixative and processed for paraffin embedding. Sections 
were stained with hematoxylin and eosin (H & E) for histological 
examination and in situ hybridization experiments. Immunolabelings 
were performed on unfixed frozen sections. The entire labeling pro- 
cedure was carried out at room temperature. All washes and re- 
agents were in PBS. The nonspecific binding sites were blocked 
in 10% normal goat serum for 30 rain. All antibodies were in- 
cubated 30 min and washed three times for 3 min each between 
the two steps. The primary antibodies were rat anti-mouse CD4 
(PharMingen, San Diego, CA) and rat anti-mouse Mac-1 
(Boehringer Mannheim Corp.). The secondary antibody was bi- 
otinylated rabbit anti-rat IgG, mouse adsorbed (Vector Labs, Inc., 
Burlingame, CA). Sections were incubated with an avidin-biotin 
peroxidase complex (ABC kit; Vector Labs, Inc.) and visualized 
with diaminobenzidine. Sections were counterstained with 
Papanicolaou stain "EA-65" or hematoxylin, dehydrated, and 
mounted. For double-immunofluorescence staining, the sequen- 
tial staining technique was used. The nAChRs were stained with 
rhodamine-conjugated ot-bungarotoxin (otBTX) (Molecular Probes, 
Inc., Eugene, OR) overnight at 4~ The next day, they were con- 
tinually stained with fluorescein-conjugated goat anti-mouse IgG 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) over- 
night at 4~ All rinses and reagents were in PBS. 
Electron Microscopy. For electron microscopy (EM) observations, 
mice were perfused with warmed 2.5% glutaraldehyde. Muscle was 
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removed and fixed in 2.5% glutaraldehyde, postfLxed in 1% O,O4, 
dehydrated in graded ethanol, and embedded in araldyte. 0.5 to 
1.0-#m sections were cut and stained with uranyl acetate and lead 
citrate before viewing with an electron microscope (model 101; 
Siemens, Karlsruhe, Germany) operating at 80 kV. 
Electromyograms. Mice were anesthetized with chloral hydrate 
(100 mg/kg) and placed on a heating pad to allow maintenance 
of body temperature at 38~ by use of a heating lamp, tempera- 
ture regulator, and thermistor probe. A stimulating needle elec- 
trode was placed at the Achilles tendon, and recording needle el c- 
trodes were inserted between the second and third and third and 
fourth digits of the left hind paw. A single supramaximal stimulus 
(4-6 V, 0.05 ms) was applied adjacent to the peroneal nerve, and 
the resulting electromyogram was recorded on an analogue storage 
oscilloscope. This was followed by a 1-s train of stimuli (the "ini- 
tial" stimulus; 4-6 V, 0.05 ms, 5 Hz), after which the amplitude 
of each of the five electromyogram (EMG) recordings was mea- 
sured from the screen and the difference between the amplitude 
of the first and fifth EMG recordings calculated as th  percentage 
change. The system was then provoked by Faradization (4-6 V, 
0.05 millisecond, 50 Hz) for 5 s before application of a other 1-s 
train of stimuli (the "provoked" stimulus; 4-6 V, 0.05millisecond 
5 Hz). A decline of1>10% in the amplitude between the first and 
fifth EMG recordings of either the initial or provoked stimuli was 
considered vidence ofneuromuscular dysfunction (18). All animals 
were coded, and the investigator was unaware of the identity of 
individual mice. 
Results 
Derivation of e-IFN-9~-transgenic Mi e. To produce trans- 
genic mice expressing IFN-y in the postsynaptic membrane 
of the neuromuscular junction, we constructed a recombinant 
DNA plasmid that fused the regulatory sequences ofthe mu- 
rine nAChR e gene (13) to the coding sequences of the rou- 
tine IFN-y gene (Fig. 1). We chose to use the e subunit of 
the nAChtL because it is the last subunit ranscribed during 
ontogeny, starting I d after birth (19). Expression of the IFN-3' 
gene from the subunit promoter would not, therefore, be 
expected to interfere with the development of neuromuscular 
junctions in embryos. Of 36 mice born, 10 proved to be trans- 
genic when analyzed by Southern blot hybridization. Trans- 
genic lines were maintained by breeding with BALB/c mice. 
Four transgenic lines were characterized extensively. Animals 
in one of these four lines weighed less than normal but had 
no apparent impairment of mobility at 5 mo of age. How- 
ever, after the sixth month (late onset), muscular weakness 
became visible. The remaining three lines had similarly re- 
duced body weights but showed locomotor impairment by 
6 wk of age, indicating the early onset of muscular weak- 
ness. In situ hybridization demonstrated the presence of IFN-7 
RNA in individual dispersed cells within the muscles of trans- 
genic mice. The observed expression pattern was consistent 
with perijunctional localization of the lymphokine in mice 
from all transgenic lines (Fig. 2). 
Characterization fAppearance and Behavior in e-IFN-~,- 
transgenic Mice. At birth, the transgenic mice appeared in- 
distinguishable from their nontransgenic littermates. How- 
ever, after weaning, their weight gain slowed, resulting in 
an ",,25% lower weight for 2-mo-old early-onset transgenic 
mice compared with their nontransgenic littermates. In late- 
onset mice, the weight differences were not as noticeable at 
this stage. The mature transgenic animals then lost 5-10% 
of thdr body weight each month during the observation period 
of 7 mo. Their fur was ruffled, and their distinctive posture 
featured a humped back and drooping head and tail, indi- 
cating muscle weakness. Further evidence of muscular dys- 
function was their slowed motion, difficulty in climbing cage 
sides, and long periods of inactivity. Enforced exercise accen- 
tuated their motor impairments. Similar motor dysfunction 
was reported for EAMG induced by the injection of nAChR 
(1, 20-25). 
Anticholinesterase Tr atment. Administration of the anti- 
cholinesterase drug neostigmine temporarily eliminated signs 
of muscle weakness, as is the case in MG. Within 15 min 
after the transgenic mice were given neostigmine (0.015 mg/kg 
body weight intraperitoneally), they began to traverse the 
cage actively and groom themselves. This restoration of motor 
activity by neostigmine suggests that an increase in the con- 
centration of acetylcholine, asa result of acetylcholinesterase 
inhibition, augmented the efficiency of neurotransmission. 
Thus, this muscular weakness seems to be a defect of neuro- 
transmission rather than the contractile properties of the 
muscle cells. 
x "# xx ~" ,, 
T I I I 
~-promoter IF N-V gene 
Figure 1. Structure of recombinant ~-IFN-y gene. The gene encoding 
IFN-3" was inserted into the BamH/restriction site of the 3.5-Kb e gene 
fragment containing the promoter region (13). An 8.8-kb Xhol/Spel frag- 
ment containing the e promoter, the IFN-"/gene, and a terminator se- 
quence were xcised and purified for oocyte injection as described previ- 
ously (14). 
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Figure 2. In situ hybridization confirming that IFN-y was expressed 
in neuromuscular junctions of e-IFN-~'-transgenic mi e. Skeletal muscles 
from 4-mo-old e-IFN-3,-transgenic mouse, x160. 
Electrophysiological Investigation. To determine whether the 
morphological changes were associated with functional dis- 
turbances, electrophysiologic testing was performed by use 
of a modification of the procedure described by Pachner and 
Kantor (18). None of nine control nontransgenic mice ex- 
hibited a change in EMG amplitude of >110% during tetanic 
(5 Hz) stimulation, either before or after provocation (Fig. 
3 A). No spontaneous EMG activity was noted in any trans- 
genic mouse, and normal biphasic EMGs were recorded after 
stimulation. Of the early-onset transgenic mice, four out 
of five exhibited decreases of i>10% in EMG amplitude 
during the initial stimulation and also after provocation (Fig. 
3 B). Decreases of I>10% were also noted in three out of 
six 6-mo-old late-onset transgenic mice during the initial 
stimulation and in five out of six after provocation (Fig. 3 
C). Neostigmine treatment attenuated the decline in EMG 
amplitude after provocation i a late-onset transgenic mouse 
that had previously shown a marked ecline (Fig. 3 D). The 
mean changes in EMG amplitude during tetanic stimulation 
for each group before and after provocation are shown in Fig. 
3 E. These decreases inelectrophysiologic test scores indicate 
a disturbance in neuromuscular transmission that dosely 
resembles that noted in MG patients (26) and EAMG sub- 
jects (18). 
Histolmthology of Muscle in E-IFN-y-transgenic Mice By light 
microscopy, H & E-stained sections of mu cles showed infiltra- 
tion by lymphocytes, polymorphonudear, and mononuclear 
cells (Fig. 4 A). Individual myofibrils showed egenerative 
changes, including the appearance oftarget fibers. Leukocyte 
cell subtypes were identified as MHC class II-expressing mac- 
rophages and occasional CD4 + T cells (Fig. 4, B and C). 
Both CD4 + T cells and macrophages are present in human 
MG and have been implicated in the generation of autoim- 
mune responses tonAChR (27). In addition, numerous plasma 
cells were identified byanti-IgG antibody in the adjacent lymph 
node. In other organs, including the thymus, no apparent 
abnormality was found. 
UltrastructuralAnalysis. EM of skeletal muscles from both 
early- and late-onset transgenic mice revealed ablation of junc- 
tional folds of the sarcolemma (Fig. 5), suggesting a reduction 
in the number of nAChK (28, 29). Strikingly, macrophages 
were consistently present adjacent to the morphologically al-
Figure 3. EMGs from control (tt) and early-onset (B) 
e-IFN-',/-transgenic mice after tetanic stimulation (30). 
A late-onset transgenic animal with a marked decline  
EMG amplitude (C) was allowed to recover f om anesthesia, 
and tetanic stimulation was repeated 80 min after treatment 
with neostigmine (0.015 mg/kg, i.p.) (D). The mean per- 
centage of decline during the initial and provoked stimuli 
was calculated for all three groups (E), and statistical com- 
parisons were made by one-way analysis of variance followed 
by the Neuman-Keuls test when the F test gave p <0.05. 
Data are mean _+ SE. 
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Figure 4. Cellular infiltrates on skeletal muscles 
from 4-mo-old e-IFN-7 mice. (.4) Limb muscle 
showing monocytic infiltration (H & E stain). (B) 
CD4 + T calls (center) and atrophic muscle fibers 
(arrows) shown by immunoperoxidase labeling. (C) 
Mac-1 * cells. For B and C, cryostat sections were la- 
beled with rat anti-CD4 or rat anti-Mac 1 antibodies. 
The secondary antibody was biotinylated rabbit anti-rat 
lgG. Sections were incubated in avidin-biotin peroxi- 
dase complex and visualized with diaminobenzidine. 
Sections were counterstained with Papanicolaou stain 
"EA-65" or hematoxylin, dehydrated, and mounted. 
x 160. 
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Figure 5. Comparison f motor end plates in the inter- 
costal muscles of control (A) and e-IFN-3,-transgenic (B) 
mice (• and • respectively). The control 
mouse has a myelinated axon (ax) terminating at the neu- 
romuscular junction with its complex junctional i foldings 
(arrows). The e-IFN-q,-transgenic mouse lacks these junc- 
tional infoldings (arrows) and displays axonal (ax) shrinkage 
as well as retraction of the Schwann ceUs (sc) from the ter- 
minal axon. 
tered neuromuscular junctions (Fig. 6). Simplification of the 
postsynaptic membrane occurs commonly in the neuromus- 
cular junctions of MG patients (30-32) or animals with chronic 
EAMG (28), but phagocytic nvasion does not. In fact, phago- 
cytic invasion of neuromuscular junctions is usually noted 
only in acute or passively transferred EAMG. Furthermore, 
in the adjacent lymph nodes, the appearance of plasma cells 
containing ultrastructural characteristics of IgG hypersecre- 
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Figure 6. Intercostal muscle from an E-IFN-3'-transgenic 
mouse. Mononuclear cells (m) were regularly noted adja- 
cent o abnormal terminal regions of axons (ax). x 12,300. 
tion (Russell bodies) indicated the activation of the humoral 
immune system. 
Autoantibody Deposition. Immunohistochemical staining 
experiments were performed with FITC-conjugated antibody 
against mouse IgG on cryostat sections of muscle from trans- 
genic and control mice. Intense staining by mouse IgG was 
visible as deposits believed to be at the motor end plates of 
skeletal muscles (Fig. 7 B). In 2-mo-old mice of the early- 
onset group, staining was restricted to a few weakly staining 
motor end plate structures. However, by 4 mo of age, in- 
tense staining of a large number of motor end plates was ob- 
served. This progression from a few weakly stained end plates 
to many strongly stained ones during the interval between 
2 and 4 mo of age correlated with the time period during 
which clinical symptoms arose. The late-onset mice showed 
a similar staining pattern only after they reached I>6 mo of 
age. The localization of IgG deposition to the motor end 
plate region was confirmed by double-labeling experiments 
using rhodamine-conjugated olBTX to probe for nAChRs. 
Indeed, the fluorescein label colocalized with the otBTX la- 
beled (Fig. 7, A and B). Our observations of the otBTX- 
labeled muscle tissues revealed that most synaptic lefts from 
transgenic mice appeared as slender elongated structures, a
shape that was quite distinct from those of nontransgenic 
mice. Furthermore, the few fairly normal appearing synaptic 
clefts of these mice were not double labeled with the fluorescei- 
nated antibody. The IgG deposits in synaptic lefts of the 
transgenic mice accumulated in circular loci, some of which 
also stained with otBTX. Such round loci were never detected 
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in tissues from nontransgenic mice tested with the olBTX 
label. Studies in which these areas were double stained with 
hematoxylin dicated that the round loci did not correspond 
to nuclei, and possibly represent capping structures of 
membrane-bound antibody. The purified IgG from e-tram- 
genic mouse sera also positively stained the motor end plates 
of BALB/c muscles (Fig. 7, C and D). No staining was ob- 
served in BALB/c muscle when purified IgG from BALB/c 
sera was used (data not shown). These r sults strongly sug- 
gest that the IFN-3' expressed in the neuromuscular junc- 
tion induced a humoral autoimmune r sponse toward com- 
ponents in the motor end plates. 
Target Antigen Detection. A large percentage of MG pa- 
tients exhibit humoral autoimmunity omotor end plate con- 
stituents, most commonly directed at the nAChR. To inves- 
tigate whether our IFN-3,-transgenic mice had a similar 
immune response, we looked directly for anti-nAChR au- 
toantibodies by use of labeled c~BTX and performed Western 
blots on purified IgG from transgenic and control mice. As 
our source of antigen, we used the mouse cell line BC3H-1, 
which expresses muscle nAChRs and is presumably derived 
from a motor end plate (33). We failed to detect any autoan- 
tibodies to nAChRs in the serum from transgenic mice (data 
not shown). Interestingly, however, we were able to consis- 
tently detect an 87-kD band on Western blots of BC3H-1 
extracts that appeared with serum from all 12 transgenic mice 
analyzed. This band id not appear when brain extracts were 
used as antigen (data not shown). 
Since a category of MG patients are "seronegative" having 
Figure 7. Detection of IgG deposition in transgenic motor end plates and the binding of transgenic IgG toBALB/c motor end plates (mouse age: 
4 mo). The motor end plate was first identified byrhodamine-conjugated otBTX. (A) Muscle from transgenic mouse; (c) muscle from BALB/c mouse. 
(/3) The presence ofIgG in the same motor end plate of a transgenic mouse was visualized by FITC-conjugated goat anti-mouse IgG. (/9) BALB/c
muscle was incubated first with transgenic IgG followed by FITC-conjugated goat anti-mouse IgG; the motor end plate was also labeled, indicating 
that transgenic mice contained antibodies to some component(s) of motor end plates. When IgG from nontransgenic control mice was used to stain 
BALB/c muscles, no staining was observed (not shown). A, B, x450; C, D, xl,000. 
no measurable anti-nAChR antibodies, we wondered whether 
the 87-kD protein found in the transgenic mice represented 
an additional target antigen that was shared with seronega- 
tive MG patients. We therefore obtained sera from seronega- 
tive MG patients and performed similar Western blot anal- 
Figure 8. Reactivity of transgenic mice and human MG patients to 
components in the BC3H-1 cell line extract. Western blotting analysis 
revealed that antibodies from individual mice and MG patients consistently 
recognized an 87-kD protein in the extracts. (Lanes 1-3) IgG from trans- 
genic mice. (Lanes 4-7) Sera from MG-seronegative patients. (Lanes 8-10) 
Sera from MG-seropositive patients. (Lanes 11-13) sera from patients with 
non-MG autoimmune disorders. Note the absence of a 87-kD band. 
ysis. Strikingly, these samples contained an 87-kD protein, 
which was labeled by sera from 15/15 seronegative MG pa- 
tients. The protein recognized by mouse purified IgG and 
human sera appeared identical in size. We also detected im- 
munoreactivity o the 87-kD band in 8/14 seropositive MG 
patients. Importantly, the 87-kD protein was not recognized 
by purified IgG from either BALB/c mice or sera from 7/8 
of nonmyasthenic patients (Fig. 8 and Table 1). To determine 
whether the 87-kD protein was similar in mice and humans, 
we performed cross-immunoprecipitation experiments. We 
immunoprecipitated extracts from the murine muscle cell line 
BCH3-1 and human tumor cell line TE671 using purified 
transgenic mouse IgG or human MG IgG, and Western blots 
were performed on the immunoprecipitated material with 
sera from the other species. We were able to detect he human 
immunoprecipitation product with the mouse IgG, and vice 
versa (Fig. 9). 
An 87-kD postsynaptic membrane protein has been previ- 
ously reported in vertebrate muscle (34, 35). To determine 
whether this 87-kD protein was the one recognized by IgG 
from transgenic mice (e-IgG), we obtained anti-87-kD- 
postsynaptic membrane protein antibodies (anti-87-kD-PSMP- 
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Table 1. Results of Western Blot Analysis in Mice and 
Seronegative and Seropositive MG Patients 
Source of IgG or Sera 
Positive 87-kD protein 
% Positive/Total 
e-IFN-3,-transgenic mice 
BALB/c mice 
Seronegative MG patients 
Seropositive MG patients 
Nonmyasthenic disorder 
100 (12/12) 
0 (0/6) 
100 (15/15) 
57.2 (8/14) 
14 (1/8) 
Crude cell extract was prepared from the BC3H-1 cell line. There was 
an 87-kD protein labeled with purified IgG from 12 transgenic mice or 
sera from 15 seronegative and 8 seropositive MG patients. This 87-kD 
protein stained negatively with purified IgG from either BALB/c mice 
or sera from most of the nonmyasthenic autoimmune disorder patients. 
One patient out of eight showed positive staining. 
Ab, a generous gift from R. Huganir) and prepared im- 
munoprecipitates from our crude extracts. The antigen su- 
pernatants were collected and allowed to reprecipitate with 
either anti-87-kD-PSMP-Ab or e-IgG. SDS-PAGE showed 
that anti-87-kD-PSMP-Ab and e-IgG each quantitatively re- 
moved its own respective protein, but failed to recognize the 
other (data not shown). These results demonstrate hat there 
was no cross-reactivity between anti-87-kD-PSMP-Ab and 
e-IgG and strongly suggest that our crude extract 87-kD pro- 
tein is not the same as postsynaptic membrane 87-kD pro- 
tein in the motor end plates. 
Discussion 
While the perturbations used to produce transgenic mice 
cannot, by definition, copy naturally occurring conditions, 
we have demonstrated some striking similarities between the 
e-IFN-3,-transgenic mice and aspects of human MG. These 
include overt muscular weakness, implification of the post- 
synaptic membrane, progressively declining EMG responses 
to stimulation, restoration of motor activity by anticholines- 
terase drugs, and infiltration of muscles by cells of the im- 
mune system. Additionally, both human MG and our trans- 
genic mice demonstrate deposition of a tibody at motor end 
Figure 9. The proteins immunoprecipitated from BCH3-1 extracts by 
use of transgenic mouse IgG or MG patient IgG. (Lane 1) Control BALB/c 
IgG. (Lanes 2-4) Probed with individual transgenic mouse IgG. (Lanes 
5-11) Probed with individual human MG patient IgG. 
plates, which in our mice occurs during the preclinical period. 
Lastly, we have demonstrated the presence of antibody directed 
against an 87-kD protein in crude mouse BC3H-1 and human 
TE671 extracts that is shared by transgenic mice, human 
seronegative MG patients, and the majority of seropositive 
MG patient sera we studied. 
The pathogenic significance of immunological sensitiza- 
tion to the 87-kD antigen remains to be determined. Prelim- 
inary immunofluorescence studies using sera from transgenic 
mice on cultured BC3H-1 cells demonstrated cell surface lo- 
calization of the 87-kD antigen. It is possible that these anti- 
bodies may bind to epitopes of a protein closely associated 
with the nAChK and are capable of modulating its function 
indirectly. The possible physical association between the 87- 
kD antigen and the nAChR is supported by the fact that 
we could detect the 87-kD band with e-IFN-3, sera on Western 
blots of partially purified nAChK. This suggests, but does 
not prove, that the 87-kD protein could coprecipitate with 
the nAChR. Previous studies have shown that Ig obtained 
from "seronegative" patients, when injected into experimental 
animals, caused loss of nAChRs and decreased amplitudes 
of motor end plate potentials, thus providing evidence for 
the presence of antibody directed against some postsynaptic 
component of the neuromuscular junction (36, 37). Our data 
on humans and mice suggest hat this antigen could be the 
87-kD band we have identified. Further experimentation is 
warranted to address this point. 
The histological lesions in this model consisted of inflam- 
matory cell infiltrates that could result from the response to 
viral infection or autoimmune disease. These inflammatory 
infiltrates, composed mainly of macrophages, were quite 
different in cellular composition from the more diverse pan- 
creatic infiltrates (including CD8 + T and B cells) previously 
observed in transgenic mice expressing IFN-3' in the islets 
of Langerhans (38). Interestingly, pancreatic expression of quite 
disparate signals such as the Th2 cytokine IL-10 are capable 
of recruiting infiltrates that are surprisingly similar in cel- 
lular composition to the pancreatic nfiltrates observed with 
IFN-3~ expression (39). Thus, identical signals (IFN-3,) lead 
to pronounced ifferences in inflammatory responses in 
different tissues, while disparate signals lead to similar ecruit- 
ment patterns in the same tissue. This might be mediated 
at the level of the tissue ndothelium, which has been demon- 
strated in vivo to respond to localized expression of IFN-'y (40). 
The expression of IFN-y leads to pathogenic responses 
mediated by distinct arms of the immune system in each tissue. 
In the neuromuscular disease of our transgenic mice, the au- 
toantibody deposits at the motor end plates imply autoim- 
munity in the humoral compartment. However, no CD8 cells 
could be identified within the transgenic musdes, implying 
the lack of participation of a cell-mediated response. This is 
quite distinct from transgenic mice expressing IFN-~/in the 
pancreas, where no humoral response could be identified by 
either islet cell antibodies or by studying the humoral response 
to specific islet constituents (41). In contrast, pancreatic ex- 
pression of IFN-3~ leads to infiltration by CD8 cells and the 
development ofcell-mediated immunity to islet constituents 
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(41, 42). This Thl lymphokine, which is associated with 
stimulating such cell-mediated responses, in the milieu of the 
neuromuscular junction induces humoral autoimmunity. This 
leads us to speculate that tissue-specific tropic factors could 
contribute to a localized immune response, enhancing, for 
example, ahumoral rather than a ceU-mediated response (such 
as is seen in human MG). Such factors might normally par- 
ticipate in a host's defense of a specific region. Indeed, access 
to "sterically" sequestered areas/antigens, such as the neu- 
romuscular junction, would necessitate emphasis on humoral 
immunity over a cell-mediated response. This effect could 
account for the disparity in the primarily humoral response 
to glutamic acid decarboxylase antigen in the brain, which 
leads to the neurological disease stiff-man syndrome, whereas 
a cell-mediated response to the same tissue-specific antigen 
in pancreatic islets is associated with the development of 
insulin-dependent diabetes mellitus (43, 44). 
The IFN-7-transgenic model is useful because of the in- 
heritable nature of trangenes, providing a mouse strain for 
prolonged experiments. In contrast, some EAMG animals 
exhibit a self-limiting disease that subsides everal months 
after primary immunization. Several differences exist between 
our transgenic model and human MG. As in EAMG (45), 
our transgenic mice had no evidence of hyperplasia or thy- 
moma in any of seven thymuses examined, whereas '~50% 
of MG patients develop hyperplasia, nd "~10% also develop 
benign or malignant tumors. Additionally, although we rou- 
tinely saw macrophages in the vicinity of disrupted neuromus- 
cular junctions, and the postsynaptic membrane displayed the 
simplification characteristic ofboth EAMG and human MG, 
the overall amount of inflammatory cell recruitment in our 
transgenic model is much higher than that reported for MG. 
This is probably due to more avid recruitment asa secondary 
phenomenon to endothelial cell activation, which is regu- 
lated by the constitutive expression of IFN-3,. 
In transgenic mice, we have demonstrated a humoral re- 
sponse to motor end plate components that results from local- 
ized lymphokine expression. Our results uggest that human 
MG could be initiated by immune defense molecules expressed 
in response to an environmental insult such as infection. Sen- 
sitization to the nAChR or other motor end plate compo- 
nents might then occur as a secondary event. Inflammation 
and autoantibodies in the neuromuscular junction can sub- 
stantially impair neuromuscular transmission a d cause clin- 
icaUy apparent muscular weakness. Although the entire 
pathway from cytokine to disease isnot totally dear, our work 
directly links such inflammatory mediators to MG. 
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